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Abstract
Objectives—Few studies have investigated the complex relationship among asthma control, 
sleep problems, and health-related quality of life (HRQOL) among children with asthma. This 
study aimed to test the longitudinal effect of asthma control status on asthma-specific HRQOL 
through the mechanism of nighttime sleep quality and daytime sleepiness.
Methods—229 dyads of asthmatic children and their parents engaged in the Patient-Reported 
Outcomes Measurement Information System (PROMIS®) Pediatric Asthma Study with 2 years of 
follow-up to assess the change of asthma control, sleep problems, and asthma-specific HRQOL. 
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The Asthma Control and Communication Instrument was used to measure asthma control status. 
Nighttime sleep quality assessment was based on difficulty falling asleep and getting up, and sleep 
disturbance. The Iowa Pediatric Daytime Sleeping Scale was used to assess daytime sleepiness. 
The PROMIS Asthma Impact Scale was used to measure asthma-specific HRQOL. Multilevel 
structural equation modeling was performed to quantify the direct and indirect effects of asthma 
control status on asthma-specific HRQOL through nighttime sleep quality and daytime sleepiness.
Results—Poorer asthma control status was directly associated with lower asthma-specific 
HRQOL at within-subject and between-subject levels (p’s<0.05); however, effects of asthma 
control on asthma-specific HRQOL were indirectly influenced through daytime sleepiness at 
within-subject level (p<0.05), and through nighttime sleep quality and daytime sleepiness at 
between-subject level (p<0.05).
Conclusions—Asthma control status is associated with asthma-specific HRQOL, and this 
association is mediated by nighttime sleep quality and daytime sleepiness. Clinicians should 
address sleep problems related to asthma control to improve HRQOL for asthmatic children.
Keywords
Asthma control; nighttime sleep quality; daytime sleepiness; health-related quality of life; 
children; multilevel structural equation modeling
1. INTRODUCTION
Asthma is a common chronic illness which affects approximately 6.9 million (9%) children 
in the United States [1]. Children with asthma are more likely to experience sleep problems 
than children without asthma [2, 3]. Depending upon different study designs and population 
characteristics, the percentage of children with asthma experiencing sleep difficulties ranged 
from 30% to 40% [4–6]. It is especially evident that children with poorly-controlled asthma 
are more likely to experience nighttime awakening and sleep difficulties than children with 
well-controlled asthma [3, 7, 8]. The relationship between sleep problems and health-related 
quality of life (HRQOL) in asthmatic children has been extensively investigated by previous 
studies. These studies found that sleep problems such as nighttime sleep disturbance [9, 10] 
and daytime sleepiness [11] were associated with poorer HRQOL in physical [9, 10], and 
mental [9, 10] health domains, as well as asthma-specific domains [11].
Studies on the complex associations among asthma control, sleep problems, and HRQOL 
are still sparse. Our previous study based on the path analytic approach has found that 
poorly-controlled asthma status was linked to great daytime sleepiness and low asthma-
specific HRQOL; more importantly daytime sleepiness significantly mediated the 
association between asthma control status and asthma-specific HRQOL [11]. Another study 
investigating the relationships of self-reported sleep quality and sleep duration assessed by 
actigraphy with psychological well-being found that variability in sleep duration over 7 days 
rather than sleep onset latency or awakening time was associated with poorer subjective 
well-being [12]. This study further found that sleep quality mediated the relationship 
between sleep duration and subjective well-being [12]. However, previous studies have 
frequently focused on a single aspect of sleep problem such as nighttime sleep quality, sleep 
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duration, or daytime sleepiness; very few studies have included multiple aspects of sleep 
problems simultaneously. Testing different aspects of sleep problems and their respective 
roles in the relationship between asthma control and HRQOL can help clarify the 
mechanisms toward designing interventions to improve HRQOL.
This study aimed to investigate the influence of nighttime sleep quality and daytime 
sleepiness on the association between asthma control and asthma-specific HRQOL based on 
the parent study, the Patient-Reported Outcomes Measurement Information System 
(PROMIS®) Pediatric Asthma Study (PAS), which was funded through the National 
Institutes of Health (NIH) between 2010 and 2015. PROMIS PAS is a longitudinal study 
collecting data of asthma control status, nighttime and daytime sleep issues, asthma-specific 
HRQOL, and psychosocial outcomes from asthmatic children and their parents across 
multiple time points. Given the nature of the repeated data, a multilevel structure equation 
modeling (MSEM) approach was specifically used to quantify the effects of asthma control 
status on asthma-specific HRQOL (defined as direct effects), and the effects of asthma 
control status on asthma-specific HRQOL through the mechanism of nighttime sleep quality 
and daytime sleepiness (defined as indirect effects). It was hypothesized that if children 
experienced poor nighttime sleep quality due to poorly-controlled asthma status, they would 
subsequently experience excessive daytime sleepiness. Poor nighttime sleep and excessive 
daytime sleepiness would in turn influence their daily functional status and asthma-specific 
HRQOL.
2. MATERIALS AND METHODS
2.1 Population and data collection
In the PROMIS PAS, 229 dyads of asthmatic children and their parents were recruited from 
Florida Medicaid and the State Children’s Health Insurance Program (SCHIP). After 
University of Florida’s institutional review board approved the research protocol, this study 
applied the same inclusion and exclusion criteria as the parent study to recruit the study 
participants, including 1) children’s age between 8 and 17.9 years old, and parents’ age 
greater than 18 years old; 2) at least 6 months continuous enrollment in Florida Medicaid 
and the SCHIP; 3) asthma diagnosis (ICD-9-CM: 493.1, 493.2 or other 493.x) listed in the 
claim and enrollment files of Florida Medicaid and the SCHIP; 4) at least two asthma-
related health care visits during the past 12 months; and 5) accessible to both the internet 
and telephone in the past 6 weeks. Children and parents who were not able to read, speak, 
and understand English were excluded from the PROMIS PAS.
Asthma control status and the corresponding nighttime sleep quality, daytime sleepiness, and 
asthma-specific HRQOL were identified through a 26-week time window across 2 years 
(Appendix 1). Briefly, asthma control status and nighttime sleep quality were reported 
weekly (26 time points in total) by parents through the study website, including the weeks 1 
through 13 in the first year and the weeks 14 through 26 in the second year. Changes in 
asthma control status were identified by comparing the control status in weeks 2 through 13 
to the baseline status assessed at week 1 of the first year (T1; baseline of the first year), as 
well as the control status in weeks 15 through 26 to the baseline status assessed at week 14 
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of the second year (T3; baseline of the second year). Asthma-specific HRQOL and daytime 
sleepiness were self-reported by children through telephone interviews at both T1 and T3.
In the PROMIS PAS, the overall asthma control status of individuals was determined by 5 
items in the Asthma Control and Communication Instrument (ACCI) measuring asthma 
control (see below), and then classified as adequately-controlled status if they answered all 5 
items as adequately-controlled; otherwise, they were classified as poorly-controlled status 
[13]. If the first asthma control status changed (worse or better) anytime between weeks 2 
and 13 in the first year, HRQoL data were collected from an affected child via a telephone 
interview during the same week (T2); likewise in the second year between weeks 15 and 
week 26 (T4). Change in asthma control status could be either from adequately-controlled to 
poorly-controlled or from poorly-controlled to adequately-controlled. However, if a child’s 
asthma control status did not change during the follow-up period, we collected HRQOL at 
the end of follow-up period of each year (T2 and T4). The uniqueness of our study design 
accounts for the individual difference in the first change of asthma control status and the 
corresponding change of HRQOL. Additionally, since asthma control status and nighttime 
sleep quality were collected prior to pediatric daytime sleepiness and asthma-specific 
HRQOL, a temporal mechanism can be established.
2.2 Measurement and instrument
The ACCI was used to assess children’s asthma control status [13]. The ACCI was 
developed based on the 2007 National Asthma Education Prevention Program Expert Panel 
Report-3 (NAEPP EPR-3) [14]. The ACCI has been validated by previous studies and has 
shown satisfactory psychometric properties including concurrent validity, discriminant 
validity, and known-group validity [13]. This instrument comprises 11 items; 5 out of the 11 
items specifically capture the concept of asthma control status (symptoms, use of rescue 
medicine, occurrence of asthma attack, activity limitation due to asthma, and nighttime 
awakenings). One open-ended item is used to collect patient-physician communication. The 
overall asthma control score of an individual is calculated by summing the scores of the five 
individual items with a range from 0 to 19. Higher scores indicate worse asthma control 
status.
Children’s nighttime sleep quality was assessed by 3 items developed by this study: 1) “Last 
week, how difficult was it for your child to settle and fall asleep after bedtime rituals?”; 2) 
“Last week, how difficult was it for your child to get up in the morning?”; and 3) “Last 
week, how many times did your child wake up during the night?”. For each item, a 5-point 
Likert-type response category ranging from “not at all difficult” to “extremely difficult” or 
from “never” to “7 times” is used. The overall sleep quality score of an individual is 
calculated by summing the scores of the 3 individual items with a range from 3 to 15. Higher 
scores represent worse nighttime sleep quality.
Children’s daytime sleepiness was measured using the Iowa Pediatric Daytime Sleeping 
Scale (PDSS) that comprises 8 items for a single dimension of daytime sleepiness. PDSS has 
shown acceptable measurement properties such as internal consistency [15]. Of the 8 items, 
7 items are related to sleepiness, and a 5-point Likert-type response category ranging from 
“always getting sleepy” to “never getting sleepy” is used. One item is related to alertness, 
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and a 5-point Likert-type response category ranging from “never being alert” to “always 
being alert” is used. All of the items are used to calculate the domain score. Higher scores 
represent worse daytime sleepiness.
In the PROMIS PAS, the PROMIS pediatric short-forms were used to collect 7 domains of 
HRQOL including asthma impact, fatigue, depressive symptoms, anxiety, pain interference, 
peer relationships, and mobility [16–19]. This study focused on asthma-specific HRQOL 
measured by the asthma impact domain. This domain comprises 8 items selected from a 
calibrated PROMIS asthma item bank developed by item response theory and qualitative 
methodologies [20, 21]. For each item, a 5-point Likert-type response category ranging from 
“never” to “almost always” is used. Scores of individual items are estimated for each child, 
with a standardized mean score of 50 and SD of 10. Higher scores represent worse asthma-
specific HRQOL.
The PROMIS PAS collected baseline socio-demographic characteristics of children and their 
parents including the children’s age, gender, race/ethnicity, height, weight, and type of 
chronic conditions, as well as the parents’ age, race/ethnicity, marital status, and education 
background. Children’s height and weight were used to calculate body mass index (BMI) 
based on the Centers for Disease Control and Prevention’s criteria [22]. Overweight was 
defined as a BMI ≥ the 85th percentile and < the 95th percentile among children and teens of 
the same age and sex.
2.3 Statistical analysis
Descriptive analyses were performed to analyze the distribution of socio-demographic 
characteristics among the study participants. The percentage or mean and standard deviation 
(SD) were calculated for the children’s age, gender, race/ethnicity, overweight status, 
number of chronic conditions, and parents’ age, race/ethnicity, marital status, education 
background, and family income. In this study, the raw scores of asthma control status, 
nighttime sleep quality, and daytime sleepiness domain were linearly transformed to a range 
between 0 (best outcomes) and 100 (worst outcomes). The transformed scores were used in 
all statistical analyses. The mean and SD of asthma control, nighttime sleep quality, daytime 
sleepiness, and asthma-specific HRQOL were reported by 4 individual time points. Bivariate 
analyses were conducted to examine the associations of asthma control status with nighttime 
sleep quality, daytime sleepiness, asthma-specific HRQOL, and participants’ socio-
demographic characteristics, respectively, through these 4 individual time points. 
Additionally, bivariate analyses were performed to test the associations of HRQOL with 
nighttime sleep quality, daytime sleepiness, and participants’ socio-demographic 
characteristics, respectively, by individual time points.
Linear random-intercept models were performed to examine the effects of asthma control, 
nighttime sleep quality, and daytime sleepiness on asthma-specific HRQOL by treating 
individual subjects as random effects to account for the clustering effects of repeated 
assessments of asthma-specific HRQOL outcomes. Different independent variables were 
included in 4 separate random-intercept models: asthma control alone (Model 1); nighttime 
sleep quality alone (Model 2); daytime sleepiness alone (Model 3); and asthma control, 
nighttime sleep quality, and daytime sleepiness (Model 4). The children’s age, gender, race/
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ethnicity, number of chronic conditions, and the parents’ age, marital status, and educational 
background were treated as covariates and included in all random-intercept models.
Multilevel structural equation modeling (MSEM) was applied to investigate the direct effect 
of asthma control status on asthma-specific HRQOL, and the indirect effect of asthma 
control on asthma-specific HRQOL through the influence of nighttime sleep quality and 
daytime sleepiness. MSEM has demonstrated several unique features compared with 
traditional path analytic methods on managing multilevel data, and has been successfully 
applied to several social behavioral studies [23–25]. First, MSEM is able to incorporate 
more than one mediator in the path analytic framework. In this study, MSEM was conducted 
to model the effect of two mediators related to sleep problems (nighttime sleep quality and 
daytime sleepiness) on the pathway between asthma control status and asthma-specific 
HRQOL. Second, MSEM is able to model various relationships among independent 
variables, mediators, and outcome variables at different levels of the data [26, 27]. In this 
study, because asthma control status, nighttime sleep quality, daytime sleepiness, and 
asthma-related HRQOL were assessed at 4 time points for each subject, the data can be 
stratified into two levels: within-subject (or repeated) variation (level 1) and between-subject 
variation (level 2). The intraclass correlations (ICC) of selected variables were examined to 
indicate if there was significant between-subject variation, which was calculated as the ratio 
of between-group variance to the total variance of that variable. ICC ≥ 0.2 suggests 
significant clustering effects in the data that should be addressed using a multilevel analytic 
framework [28–30]. Third, MSEM can accommodate missing data and unequal cluster sizes 
in multilevel study designs [27]. Finally, the use of MSEM allows for adjustment of 
participants’ socio-demographic factors assumed to confound the associations among 
variables.
The analytic framework (Figure 1) for MSEM was developed based on Preacher and 
colleagues’ methodology [27]. The longitudinal design of the PROMIS PAS results in two-
level data for statistical analyses: individual values of each variable collected from 4 
repeated assessments (i.e., within-subject level) and the mean estimated value of 4 repeated 
assessments from an individual (i.e., between-subject level). Using information of within-
subject and between-subject variance, the relationships among asthma control status, sleep 
problems, and asthma-specific HRQOL were tested using the scores of latent variables 
(ovals in Figure 1) that were estimated from the observed variables (rectangles in Figure 1) 
collected from 4 time points. Monte Carlo simulation was performed to estimate the 
unbiased confidence intervals (CIs) for indirect effects of asthma control status on asthma-
specific HRQOL through nighttime sleep quality and daytime sleepiness. Several studies 
have reported that Monte Carlo simulation would provide precise CIs when a bootstrap 
method is not feasible in multilevel context [26, 31, 32]. In this study, Mplus 7.11 (Muthén 
and Muthén, Los Angeles, CA) was used to perform multilevel path analyses, and SAS 9.3 
(SAS Institute, Cary, NC, USA) was used to implement the remaining analyses.
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3. RESULTS
3.1. Participant characteristics
Table 1 shows study participants’ characteristics. For children at the baseline of the study in 
the first year (N=229), the mean age was 12.2 years old (SD: 2.6); 59.0% were boys; 38.0% 
were non-Hispanic White; and 17.0% had hyperactivity or attention deficit disorder, and 
45.0% were overweight. For parents, the mean age was 40.6 years old (SD: 8.7); 51.5% 
were married; most had an educational background of some college, associate degrees or 
college degrees (60.2%); and family income was largely between $15,000 and $35,000 
(45.5%).
3.2. Score distribution for the variables of interest
Table 2 shows the results of descriptive analyses for asthma control, nighttime sleep quality, 
daytime sleepiness, and asthma-specific HRQOL across 4 time points. The scores of these 
variables were highest at T1, and declined over time. The tests for this trend on the score 
change over time were indicated by F values, which were significant for nighttime sleep 
quality (p<0.001), daytime sleepiness (p<0.01), and asthma-specific HRQOL (p<0.01).
3.3. Bivariate associations
Table 3 shows the bivariate associations of HRQOL with asthma control, nighttime sleep 
quality, daytime sleepiness and participants’ socio-demographic characteristics, respectively. 
Data collected from 4 time points were treated as 4 waves of cross-sectional data. 
Specifically, HRQOL was positively associated with asthma control, nighttime sleep quality, 
and daytime sleepiness at individual time points (p’s<0.01). Poorer HRQOL was associated 
with being male children at T4 (p<0.05). Children of parents with a high school education or 
below were more likely to have impaired asthma-specific HRQOL than those whose parents 
had a college degree or above in all four models (p’<0.05) at T1 and T2.
Bivariate associations of asthma control with nighttime sleep quality, daytime sleepiness, 
asthma-specific HRQOL, and participants’ socio-demographics were presented in Appendix 
2. Asthma control status was positively associated with nighttime sleep quality in individual 
time points (p’s<0.001). Poorer asthma control was associated with greater daytime 
sleepiness at T1 and T4 (p’s<0.01). Poorer asthma control was associated with lower 
asthma-specific HRQOL in individual time points (p’s<0.001). Children with more chronic 
conditions had poorer asthma control at T1 and T3 than those with fewer chronic conditions 
(p’s<0.05).
3.4. Multivariate associations
Table 4 shows the associations of asthma-specific HRQOL with asthma control, nighttime 
sleep quality, daytime sleepiness, and participants’ characteristics estimated by linear 
random-intercept models. After adjusting for participants’ characteristics, Model 1 reveals 
that poorer asthma control was significantly associated with lower asthma-specific HRQOL 
(β: 0.17; p<0.001); Model 2 shows poorer nighttime sleep quality was significantly 
associated with lower asthma-specific HRQOL (β: 0.12; p<0.001); and Model 3 shows 
greater daytime sleepiness was significantly associated with lower asthma-specific HRQOL 
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(β: 0.21; p<0.001). When taking asthma control, nighttime sleep quality and daytime 
sleepiness into consideration (Model 4), only poorer asthma control status (β: 0.14; p<0.001) 
and greater daytime sleepiness (β: 0.19; p<0.001) were significantly associated with lower 
asthma-specific HRQOL. Children of parents with a high school education or below were 
more likely to have impaired asthma-specific HRQOL than those whose parents had a 
college degree or above in all four models (all p’s<0.05).
3.5. Direct and indirect effects of asthma control on asthma-specific HRQOL
ICCs for the repeated measurements of asthma control, nighttime sleep quality, daytime 
sleepiness, and asthma-specific HRQOL were 0.21, 0.48, 0.58, and 0.52, respectively. These 
values were greater than the threshold 0.20, suggesting the existence of clustering effects of 
the data and the importance of using MSEM approach.
Table 5 shows the estimated coefficients for the variables at both within-subject and 
between-subject levels in the path analyses based on the MSEM. At the within-subject level, 
the individual scores of 4 repeated measurements on asthma control, nighttime sleep quality, 
daytime sleepiness, and asthma-specific HRQOL were used to interpret the relationships 
among these variables. Results revealed that poorer asthma control status was significantly 
associated with poorer nighttime sleep quality (β: 0.35; p<0.05), greater daytime sleepiness 
(β: 0.09; p<0.05), and lower asthma-specific HRQOL (β: 0.12; p<0.05), respectively. 
Additionally, greater daytime sleepiness was significantly associated with lower asthma-
specific HRQOL (β: 0.15, p<0.05). The coefficient, for example 0.15, can be interpreted as 
an increase of daytime sleepiness by 1 unit, was associated with an increase of asthma-
specific HRQOL by 0.15 units. However, poorer nighttime sleep quality was not 
significantly associated with greater daytime sleepiness (β: 0.09; p>0.05) and lower asthma-
specific HRQOL (β: 0.03; p>0.05). The estimated magnitude of the indirect effect of asthma 
control status on asthma-specific HRQOL was 0.01 through the influence of daytime 
sleepiness (p<0.05); 0.01 through the influence of nighttime sleep quality (p>0.05); and 0.01 
through both nighttime sleep quality and daytime sleepiness (p>0.05). In other words, at the 
within-subject level, daytime sleepiness rather than nighttime sleep quality significantly 
explained or mediated the relationship between asthma control status and asthma-specific 
HRQOL.
At the between-subject level, the estimated mean scores of four repeated measurements on 
asthma control, nighttime sleep quality, daytime sleepiness, and asthma-specific HRQOL 
were used to interpret the relationships among these variables. Results revealed that poorer 
asthma control status was significantly associated with poorer nighttime sleep quality (β: 
1.04, p<0.05) and lower asthma-specific HRQOL (β: 0.72, p<0.05); however, asthma control 
was not significantly associated with daytime sleepiness (β: −0.37, p>0.05). Additionally, 
poorer nighttime sleep quality was significantly associated with greater daytime sleepiness 
(β: 0.69, p<0.05), but not with asthma-specific HRQOL (β: −0.26, p>0.05). Greater daytime 
sleepiness was significantly associated with poorer asthma-specific HRQOL (β: 0.30, 
p<0.05). The estimated magnitude of the indirect effect of asthma control on asthma-specific 
HRQOL was −0.27 through nighttime sleep quality (p>0.05); −0.01 through daytime 
sleepiness (p>0.05); and 0.22 through both nighttime sleep quality and daytime sleepiness 
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(p<0.05). In this regard, at the population level, poorer sleep quality and greater daytime 
sleepiness significantly explained or mediated the association between asthma control and 
asthma-specific HRQOL.
4. DISCUSSION
We used an innovative MSEM methodology to investigate the complex pathways from 
asthma control status to HRQOL through the effect of nighttime sleep quality and daytime 
sleepiness among children with asthma. We found that poorer asthma control status was 
significantly associated with lower asthma-specific HRQOL at within-subject (or individual) 
and between-subject (or population) levels. However, the effect of asthma control status on 
asthma-specific HRQOL was explained through daytime sleepiness at the within-subject 
level, and through both nighttime sleep quality and daytime sleepiness at the between-
subject level. Because asthma control status and nighttime sleep quality were reported prior 
to daytime sleepiness and asthma-specific HRQOL assessments, the identified pathways 
could represent causal relationships.
Our findings contribute to the literature by specifying nighttime sleep quality and daytime 
sleepiness as two important mediators that jointly contribute to the association of asthma 
control with asthma-specific HRQOL at the population level. Additionally, results derived 
from the within-subject level indicated that increasing poor asthma control contributed to 
greater daytime sleepiness, which in turn contributed to poorer asthma-specific HRQOL. 
Taken together, our results reveal the effect of asthma control status on asthma-specific 
HRQOL is not straightforward, meaning that the association of worse asthma control with 
impaired asthma-specific HRQOL is through a dynamic process and multiple aspects of 
sleep problems in asthmatic children. Literature suggests that asthma status tends to be 
worse at night due to circadian rhythms and decreased lung function, which leads to more 
symptoms such as coughing, nocturnal awakenings, and excessive daytime sleepiness [5, 
33].
At between-subject level, the beta coefficient of the indirect effect of asthma control on 
HRQOL through nighttime sleep quality and daytime sleepiness is 0.22, which suggests that 
the 1 unit change in asthma control is associated with 0.22 unit change of HRQOL. Our 
recent study has reported that the minimally important difference of PROMIS pediatric 
measures ranged from 0.2 to 0.3 points on 1 SD metric [34]. Therefore, a small change of 
asthma control status on average is associated with a significant change of HRQOL that is 
perceived as meaningful by children and parents.
In this study, 3 items were used to measure nighttime sleep quality (difficulty falling asleep, 
difficulty getting up, and sleep disturbance). However, the use of this simple, generic 
measure may not cover the full spectrum of sleep quality, potentially leading to low 
sensitivity to detect the changes of nighttime sleep quality for children over time. This may 
explain why the mean nighttime sleep quality and daytime sleepiness mediated the effect of 
asthma control status on asthma-specific HRQOL at the population level, but the effect of 
nighttime sleep quality over time was not linked to either daytime sleepiness or asthma-
specific HRQOL at the individual level. Using 3 items to assess sleep quality was prone to 
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misclassification of poor sleep quality, and they may not accurately capture the changes of 
nighttime sleep quality. Future studies should use standard nighttime sleep quality measures 
to examine the influence of variations in nighttime sleep quality on the asthma control-
HRQOL pathway.
Given that nighttime sleep quality and daytime sleepiness are important factors influencing 
the association of asthma control status with HRQOL, assessing and treating multiple 
domains of sleep problems may directly benefit children with asthma regarding HRQOL 
improvement, especially those who have poorer asthma control status. Specifically, 
physicians could explore asthmatic children’s sleep history and assess nighttime sleep 
quality and daytime sleepiness on a regular basis. A brief screening on sleep history would 
be valuable for determining if interventions addressing sleep quality are needed to improve 
asthmatic children’s HRQOL. Previous studies have reported several therapeutic strategies 
that effectively improve sleep for children with asthma or other chronic diseases [35–37]. 
For example, the use of melatonin has significantly reduced sleep latency and the number of 
awakenings for general children with chronic insomnia [35]. Allergic rhinitis, a common 
comorbid condition co-occurring with asthma, is also related to sleep problems [38, 39]; 
therefore, managing rhinitis symptoms and maintaining nasal patency could be an effective 
way to improve sleep quality for asthmatics with rhinitis [36, 37]. Additionally, cognitive-
behavioral therapy such as relaxation and stress reduction strategies could be prescribed for 
improving sleep quality and reducing sleep disturbance for children and adolescents with 
insomnia [40, 41]. Future studies need to test the effect of these therapeutic strategies to 
address sleep problems associated with poor asthma control status.
Very few instruments are available to measure self-reported sleep problems for children and 
adolescents. A newly developed instrument, the Children’s Report of Sleep Patterns (CRSP), 
is able to measure the concepts of sleep pattern, sleep hygiene, and sleep disturbances for 
children [42]. Although our study has established a conceptual framework for testing the 
influence of nighttime sleep quality and sleepiness on the relationship of asthma control 
status with HRQOL, future studies are encouraged to apply the CRSP among other 
instruments to validate our framework by investigating the impact of different aspects of 
sleep problems on HRQOL among children with asthma.
There are several limitations that should be noted when interpreting the results of this study. 
First, the study participants were from the Florida Medicaid and the SCHIP, and most of the 
participants were recruited from families with low economic status. Therefore, our findings 
may not generalize to other populations. However, this population is vulnerable because they 
are likely to have the high rate of health disparities due to asthma. Second, multiple allergic 
factors (e.g., allergic rhinitis) might confound or mediate the relationship between asthma 
control status and asthma-specific HRQOL. A detailed history of allergies was not collected 
in this study but should be included in future research. Third, the present study focused on 
two dimensions of sleep problems and did not include other important sleep parameters such 
as sleep duration and sleep disordered breathing (SDB). Previous research has found that 
sleep duration and SDB may influence the relationship between asthma control and HRQOL 
[43–45]. Further studies need to included other dimensions of sleep problems and accurately 
quantify children’s sleep duration at night by using objective measures such as actigraphy. 
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Finally, the number of participants used for analyses decreased (28%) from the baseline (T1) 
to the end of study (T4) (Table 2). We found that there were no significant differences 
between those who did or did not remain at T4 for analyses in terms of the child’s race/
ethnicity, number of chronic conditions, and parental age, educational background, and 
marital status (all p’s>0.05). However, children who remained at T4 were slightly younger 
than those did not remain at T4 (p=0.03). Because a child’s age at different time points was 
not associated with asthma control status, nighttime sleep quality, daytime sleepiness, and 
HRQOL, we believe the impact of a child’s age on our current findings would be small.
In conclusion, our study found that asthma control status was associated with asthma-
specific HRQOL, and this association was explained partly by the influence of nighttime 
sleep quality and daytime sleepiness. Interventions to address sleep quality and daytime 
sleepiness may help to minimize the negative effect of poor asthma control on HRQOL in 
pediatric populations.
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Appendix 1: The study design to identify the changed of asthma control 
status
Appendix 2: Bivariate association of asthma control status with socio-
demographics, nighttime sleep quality, daytime sleepiness, and asthma-
specific HRQOL, respectively, by individual time points
Differences in asthma control scores between levels of categorical variables of interest
T1 T2 T3 T4
Categorical variables Mean
(SD)
T- or F-
value
Mean (SD) T- or F-
value
Mean (SD) T- or F-
value
Mean (SD) T- or F-
value
Child’s gender
Female 16.54
(18.58) −0.23
15.00
(16.92) −0.39
15.35
(17.55) −0.02
13.75
(16.24) −0.05
Male 17.13
(18.78)
16.02
(18.47)
15.43
(20.18)
13.89
(16.74)
Child’s race/ethnicity
White 14.05
(15.97)
12.96
(13.05)
12.54
(16.69)
13.91
(14.90)
Black 21.34
(21.03) 1.98
18.13
(20.52) 0.91
20.11
(20.21) 1.44
13.62
(17.90) 0.01
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Differences in asthma control scores between levels of categorical variables of interest
T1 T2 T3 T4
Categorical variables Mean
(SD)
T- or F-
value
Mean (SD) T- or F-
value
Mean (SD) T- or F-
value
Mean (SD) T- or F-
value
Hispanic 15.75
(18.66)
16.42
(20.88)
14.89
(19.70)
14.10
(15.64)
Other 20.00
(20.93)
16.76
(16.20)
13.53
(20.67)
13.53
(20.29)
Education
High school or below 19.79
(18.91) −1.63
12.89
(13.06) 1.52
16.76
(16.27) −0.69
13.53
(14.74) 0.03
College degree or 
above
15.38
(18.36)
16.56
(19.37)
14.55
(19.96)
13.62
(16.68)
Parent’s marital status
Married 14.87
(17.11) −1.66
14.65
(16.59) −0.76
13.62
(18.77) −1.27
12.96
(15.75) −0.68
Others 19.05
(20.05)
16.61
(19.05)
17.37
(19.27)
14.74
(17.26)
Smoking status at 
home
No 19.23
(18.23)
23.79
(23.49)
15.86
(18.23)
15.19
(18.25)
Yes 16.37
(18.76)
0.87 13.85
(15.88)
2.32* 15.29
(19.27)
0.15 13.56
(16.16)
0.46
Correlation of asthma control scores with other continuous variables of interest
T1 T2 T3 T4
Continuous variables Correlation coefficient Correlation coefficient Correlation coefficient Correlation coefficient
Child’s age in years 0.04 −0.06 −0.10 −0.15
Number of chronic 
conditions
0.14* 0.14 0.26*** 0.13
Parent’s age in years −0.06 0.00 −0.08 −0.09
Nighttime sleep qualitya 0.51*** 0.50*** 0.45*** 0.51***
Daytime sleepinessa 0.29*** 0.12 −0.03 0.20**
Asthma-specific HRQOLa 0.41*** 0.37*** 0.38*** 0.30***
Abbreviations: SD, standard deviation; HRQOL, health-related quality of life.
a
Higher scores indicate worse asthma control, worse nighttime sleep quality, greater daytime sleepiness and worse asthma-
specific HRQOL.
*p<0.05;
**p<0.01;
***p<0.001.
Li et al. Page 15
Sleep Med. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
A framework depicts the associations among asthma control status, sleep problems, and 
HRQOL at within-subject and between-subject levels
Socio-demographics include the child’s age, gender, race/ethnicity, number of chronic 
conditions, and the parent’s age, education background and marital status. Index: i indicates 
the time points (i=1, 2, …, 4), and j indicates the study subjects (j=1, 2, …, 229)
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Table 1
Characteristics of study participants at baseline of the first year (N=229)
Characteristics Number of subject (%)
or mean (SD)
Child’s age in years 12.24 (2.57)
Child’s gender, %
    Male 135 (58.95%)
    Female 94 (41.05%)
Child’s race/ethnicity, %
    White/non-Hispanic 87 (37.99%)
    Black/non-Hispanic 59 (25.76%)
    Hispanic 63 (27.51%)
    Other 20 (8.73%)
Child’s overweight status, % 95 (45.02%)
Most common child’s chronic conditions, %
    Attention-deficit/hyperactivity disorder 39 (17.03%)
    Premature birth 26 (11.35%)
    Mental health conditions such as depression,
anxiety, bipolar disorder and other 7 (3.06%)
    Epilepsy or other seizure disorders 6 (2.62%)
    Inflammatory bowel syndrome, Chron’s
disease or other intestinal disorder 5 (2.18%)
    Deaf or hard of hearing 5 (2.18%)
Parent’s age in years 40.60 (8.69)
Parent’s race/ethnicity, %
    White/non-Hispanic 97 (42.36%)
    Black/non-Hispanic 60 (26.20%)
    Hispanic 59 (25.76%)
    Other 13 (5.68%)
Parent’s education background, %
    High school or below 74 (32.74%)
    Some college/ technical/associated degree
and college degree 136 (60.18%)
    Advanced degree 16 (7.08%)
Family income,%
    < $14,999 47 (20.52%)
    $15,000– $34,999 102 (44.54%)
    $35,000 –$54,999 57 (24.89%)
    >55,000 23 (10.04%)
Parent’s marital status,%
    Married 118 (51.53%)
    Divorced 45 (19.65%)
    Living with partner in committed relations 10 (4.37%)
    Separated 9 (3.93%)
Sleep Med. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 18
Characteristics Number of subject (%)
or mean (SD)
    Other 40 (14.47%)
Abbreviation: SD, standard deviation
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